about
Moving forward with reactive oxygen species involvement in antimicrobial lethalityEscherichia coli genes that reduce the lethal effects of stress.Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell deathMulticolor combinatorial probe coding for real-time PCRSelective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesisMutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.A toxin-antitoxin module in Bacillus subtilis can both mitigate and amplify effects of lethal stress.Lethal synergy involving bicyclomycin: an approach for reviving old antibioticsReactive oxygen species and the bacterial response to lethal stressRibosomal elongation factor 4 promotes cell death associated with lethal stressInvolvement of Holliday junction resolvase in fluoroquinolone-mediated killing of Mycobacterium smegmatis.Resveratrol Antagonizes Antimicrobial Lethality and Stimulates Recovery of Bacterial Mutants.Inhibitors of reactive oxygen species accumulation delay and/or reduce the lethality of several antistaphylococcal agents.YihE kinase is a central regulator of programmed cell death in bacteriaMutant selection window hypothesis updated.Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.Quinolone-mediated bacterial death.Dimethyl Sulfoxide Protects Escherichia coli from Rapid Antimicrobial-Mediated KillingSpoligotyping of Mycobacterium tuberculosis Complex Isolates by Use of Ligation-Based Amplification and Melting Curve AnalysisSelection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Lateral flow immunoassay using europium chelate-loaded silica nanoparticles as labels.Contribution of oxidative damage to antimicrobial lethality.Lethal action of quinolones against a temperature-sensitive dnaB replication mutant of Escherichia coli.Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol.Low correlation between MIC and mutant prevention concentration.Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance.Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?Suppression of reactive-oxygen-species accumulation accounts for paradoxical bacterial survival at high quinolone concentration.Contribution of reactive oxygen species to thymineless death in Escherichia coli.Minimising moxifloxacin resistance with tuberculosis.Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus.The mutant selection window in rabbits infected with Staphylococcus aureus.
P50
Q26995546-0ECA961A-12E7-46F4-A56C-7BEAD5EC7B7FQ33529310-9BF52B45-DDCC-4FFD-AA4C-804DDCF99E33Q33556083-5FE7A62D-9DFF-4B42-AA83-9C7639DB11C9Q33636218-4AAE12AD-3FBC-41E4-A980-5AE9F3D2FAABQ33802657-8CDD2874-3D54-479A-9366-2176DE1DD18FQ33980255-FA1A1F8D-6836-4654-A182-FAB01CE0EC14Q33981343-07D8F3BA-E905-4125-9D4E-85B8ED2E54AEQ34012810-839A68C8-DDBB-45B2-8E25-CCF5173BFBC1Q34431951-C7ED3391-6705-4027-859C-D54200B9A4A7Q34624207-D0BEB579-4EB7-4EA6-B005-B9A78A36354EQ35072151-8CB73FE7-932C-4E3A-A704-40461A3FF65CQ35076827-289261EB-68D1-4455-8B37-940D83FF4285Q35979673-310C8213-BAFB-4B2C-92E8-27564A7992CFQ36364252-403B7C7B-CF1A-471A-A5B3-5432748E8404Q36674733-35D3FE08-B449-49AF-A0A9-052B3066A9FCQ36728061-8975A3F0-00A9-4853-87C8-867257FDC84DQ36817994-44B61E15-CA52-4E42-A7B9-EEB51EB08B90Q36921143-21B86BE7-422A-4B96-89B7-6E821AE869B5Q37120114-BEAF9CCF-AEFB-41DF-98A6-56665979ABA5Q37218616-788890E0-7048-4D55-9065-C1E4E19142C0Q39651272-03BA5CE6-9648-42A0-9901-44599C3531FAQ39731893-C550C5FE-1259-4D4C-B5A5-9A67071F57AFQ39860875-99532D1F-3CAE-43DF-AF18-9C7C3929B5C8Q41808795-DB002B07-29C3-4289-A2EC-BCFB63757CB3Q42006060-D8209276-187F-47FF-95BF-B9DB8AFA6367Q42727166-FDD91E17-615D-4836-846B-A8C4B8F0FF87Q42727522-3B42F0F7-FC8C-45FE-A625-01B42A358803Q42943040-1F98834A-A02D-42A6-B7D5-FC0D6D071837Q43189750-C15B3A5F-5063-4959-9538-38D022B6C35EQ43634714-EA2B27A9-794E-4ABD-8F5B-5322D9721A91Q43896553-666470C7-6337-4C37-9D27-0ABD83AD8894Q44462499-265B7FBA-EAC8-4AE9-9CA5-A2E3FBF4754CQ44570717-B7726645-2028-4BE2-A711-A49DFDDAB67BQ44958338-4F33068B-20F2-4995-8540-681858E7687AQ46243490-A4E9CA26-04DD-4E66-A3C1-126FC32DFC6AQ46296693-C8C74FD1-1723-4CC9-9ADD-E6055BC0E2E2Q46601628-74C6AB78-D173-4B0B-B02F-42AF5432FD20Q46904105-1E9DDBE8-BEA6-4FEF-9209-7CC02D711B7BQ46974294-E1A2201C-89FD-4F0B-A111-702AAD005140Q51109317-7D95D670-C102-4E56-AD5F-E65F6C2DA23F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Xilin Zhao
@ast
Xilin Zhao
@en
Xilin Zhao
@es
Xilin Zhao
@nl
Xilin Zhao
@sl
type
label
Xilin Zhao
@ast
Xilin Zhao
@en
Xilin Zhao
@es
Xilin Zhao
@nl
Xilin Zhao
@sl
prefLabel
Xilin Zhao
@ast
Xilin Zhao
@en
Xilin Zhao
@es
Xilin Zhao
@nl
Xilin Zhao
@sl
P108
P106
P1153
7407575230
P31
P496
0000-0001-8375-8658